Letters to the Editor
11 September 2025
Early Access
Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
105
Views
106
Downloads
Authors
Dear Editor,
A 50-year-old Caucasian male presented with a 30-year history of facial vitiligo, primarily affecting the chin and the perioral and periorbital regions. He had undergone multiple treatments over the years, including targeted phototherapy, topical corticosteroids, and calcineurin inhibitors, with limited success. [...]
Altmetrics
Downloads
Download data is not yet available.
Citations
1. Tavoletti G, Avallone G, Conforti C, et al. Topical ruxolitinib: A new treatment for vitiligo. J Eur Acad Dermatol Venereol 2023;37:2222-30. DOI: https://doi.org/10.1111/jdv.19162
2. Park JJ, Little AJ, Vesely MD. Treatment of cutaneous lupus with topical ruxolitinib cream. JAAD Case Rep 2022;28:133-5. DOI: https://doi.org/10.1016/j.jdcr.2022.08.038
3. Huang MY, Armstrong AW. Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Indian J Dermatol Venereol Leprol 2023;90:30-40. DOI: https://doi.org/10.25259/IJDVL_15_2023
4. Hussein AFA, Shams AS, Hosny N, et al. A meta-analysis of therapeutic trials of topical ruxolitinib cream for the treatment of vitiligo: therapeutic efficacy, safety, and implications for therapeutic practice. Arch Dermatol Res 2024;316:518. DOI: https://doi.org/10.1007/s00403-024-03267-8
5. Jung JIUtama A, Wijesinghe R, Thng S. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review. Int J Dermatol 2024;63:1020-35. DOI: https://doi.org/10.1111/ijd.17157
6. Inoue S, Suzuki T, Sano S, Katayama I. JAK inhibitors for the treatment of vitiligo. J Dermatol Sci 2024;113:86-92. DOI: https://doi.org/10.1016/j.jdermsci.2023.12.008
7. Kim JY, Kim MH, Park JK, et al. Successful treatment of hemophagocytic lymphohistiocytosis in a patient with systemic lupus erythematosus with ruxolitinib: a case report. J Rheum Dis 2024;31:125-9. DOI: https://doi.org/10.4078/jrd.2023.0027
8. Gorham NC, Jacobs J, Wu SZ. Response of Severe Lupus Miliaris Disseminatus Faciei to Treatment With Ruxolitinib Cream. JAMA Dermatol 2023;159:790-1. DOI: https://doi.org/10.1001/jamadermatol.2023.0528
9. Fetter T, Smith P, Guel T, et al. Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions. Front Immunol 2020;11:344. DOI: https://doi.org/10.3389/fimmu.2020.00344
10. Piccolo V, Mazzatenta C, Bassi A, et al. COVID vaccine-induced lichen planus on areas previously affected by vitiligo. J Eur Acad Dermatol Venereol 2022;36:e28-30. DOI: https://doi.org/10.1111/jdv.17687
How to Cite
Targeting JAK/STAT signaling: ruxolitinib cream in the management of concurrent vitiligo and discoid lupus erythematosus. (2025). Dermatology Reports. https://doi.org/10.4081/dr.2025.10458
Copyright (c) 2025 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
